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Asthma is an increasingly common disorder, affecting 5–10% of the population. It involves a dysregulated immune function, which
may predispose to subsequent cancer. We examined cancer risk among Swedish subjects who had hospital admission once or
multiple times for asthma. An asthma research database was created by identifying asthma patients from the Swedish Hospital
Discharge Register and by linking them with the Cancer Registry. A total of 140425 patients were hospitalised for asthma during
1965–2004, of whom 7421 patients developed cancer, giving an overall standardised incidence ratio (SIR) of 1.36. A significant
increase was noted for most sites, with the exception of breast and ovarian cancers and non-Hodgkin’s lymphoma and myeloma.
Patients with multiple hospital admissions showed a high risk, particularly for stomach (SIR 1.70) and colon (SIR 1.99) cancers.
A significant decrease was noted for endometrial cancer and skin melanoma. Oesophageal and lung cancers showed high risks
throughout the study period, whereas stomach cancer increased towards the end of the period. The relatively stable temporal trends
suggest that the asthmatic condition rather than its medication is responsible for the observed associations.
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Asthma is an obstructive lung disease in which recurrent
bronchospasms cause breathing difficulties, dyspnoea and wheez-
ing (Holgate and Polosa, 2006). The prevalence of asthma has
increased during the past decades and according to a US survey,
8.9% of the adult population has ever been diagnosed with asthma
(Scheller et al, 2006). The annual incidence rate for adults has been
2.2 cases per 1000 persons in the Nordic countries (Toren et al,
2004). An improved hygiene and a drop in exposure to viral and
bacterial infections are thought to explain part of the increase
(Maddox and Schwartz, 2002; Oh et al, 2004; Yeatts et al, 2006). An
enhanced TH2 immune response followed by an increased
production of cytokines of type IL-4 and IL-5 are thought to
contribute to the development of asthma (Ngoc et al, 2005).
Corticosteroids and b-adrenergic bronchodilators have been the
principal medication for asthma, and from about 1970 these have
been administered by inhalation (Chu and Drazen, 2005; Bateman
et al, 2008). As newer agents were introduced in the 1990s,
antileukotrienes targeted the bronchoconstrictor and anti-IgE
block circulating IgE (Chu and Drazen, 2005). The changing
asthma treatment in Sweden between 1980 and 1991 led to a 3.8-
fold increase in the cost of pharmaceuticals, mainly inhaled
corticosteroids, which in turn decreased the need for hospital
admissions by 35% in the same period (Jacobson et al, 2000;
Bateman et al, 2008).
The immune system has important functions against tumour
formation (Swann and Smyth, 2007). Thus, dysregulation of the
immune function in conditions such as asthma could potentially
lead to cancer development. Some earlier studies have evaluated
the association between a history of asthma and cancer occurrence,
but the results have been inconsistent (Alderson, 1974; Vena et al,
1985; Markowe et al, 1987; Reynolds and Kaplan, 1987; Kallen et al,
1993; Vesterinen et al, 1993; Ye et al, 2001; Boffett et al, 2002;
Soderberg et al, 2006). Many earlier studies have been small in size
and short in follow-up time. To overcome these limitations, we
carried out a longitudinal cohort study to quantify the subsequent
cancer risk in hospitalised asthma patients, using the Swedish
nationwide registers. This study is by far the largest one published
on the theme, covering 140425 patients and allowing a separate
analysis of patients with multiple hospital admissions and thus
with chronic asthma.
PATIENTS AND METHODS
We used the Swedish Hospital Discharge Register, founded in
1964–65 by the National Board of Health and Welfare with a
complete nation-wide coverage since 1987, to create a cohort of
asthma patients. Only those patients with hospital admission on
account of asthma were included in this study. These patients were
retrieved from the registry according to the seventh (1964–68 code
241), eighth (1969–86 code 493), ninth (1987–96 code 493), and
tenth (1997– code J45 and J46) International Classification of
Diseases (ICD) codes. However, outpatients were not included in
the Swedish Hospital Discharge Register, and therefore these
patients were not included in our study. A total of 140425 patients
were identified in the registry. The study cohort was linked to the
national Swedish Cancer Registry, founded in 1958 with close to
100% coverage, to ascertain all incident cancers from the start of
follow-up until 31 December 2004. The Cancer Registry used a
four-digit code according to ICD-7 to identify malignant tumours
during the study period. Additional linkages were carried out to
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ythe national census data to obtain individual occupational status,
to the National Registry of Causes of Death to identify the date of
death, and to the Emigration Registry to identify the date of
emigration. All linkages were carried out by the use of an
individual national identification number that is assigned to each
person in Sweden for his or her lifetime. This number was replaced
by a serial number for each person in order to provide anonymity.
Person-years were calculated from the last hospital admission
for asthma until diagnosis of cancer, death, emigration or closing
date (31 December 2004), whichever came first. The follow-up time
Table 1 SIR for subsequent cancer in patients with hospitalised asthma during the follow-up time
Follow-up interval (years)
o11 – 45 – 9 X10 All All 1+
Cancer site O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 20 1.77 (1.08, 2.73) 37 1.11 (0.78, 1.53) 36 1.26 (0.88, 1.74) 42 1.09 (0.79, 1.48) 135 1.21 (1.01, 1.43) 115 1.14 (0.94, 1.37)
Oesophagus 9 1.99 (0.90, 3.79) 29 2.14 (1.43, 3.08) 28 2.39 (1.59, 3.46) 19 1.20 (0.72, 1.88) 85 1.87 (1.49, 2.31) 76 1.85 (1.46, 2.32)
Stomach 49 2.41 (1.78, 3.18) 98 1.72 (1.40, 2.10) 44 0.96 (0.70, 1.30) 68 1.20 (0.94, 1.53) 259 1.44 (1.27, 1.63) 210 1.32 (1.15, 1.51)
Colon 98 2.34 (1.90, 2.85) 225 1.77 (1.55, 2.02) 170 1.54 (1.32, 1.79) 210 1.42 (1.24, 1.63) 703 1.65 (1.53, 1.77) 605 1.57 (1.45, 1.70)
Rectum 49 2.12 (1.57, 2.81) 82 1.18 (0.94, 1.47) 72 1.20 (0.94, 1.51) 108 1.33 (1.09, 1.61) 311 1.33 (1.19, 1.49) 262 1.24 (1.10, 1.40)
Liver 48 2.94 (2.17, 3.90) 89 1.88 (1.51, 2.31) 59 1.51 (1.15, 1.95) 49 0.99 (0.73, 1.31) 245 1.61 (1.41, 1.82) 197 1.45 (1.25, 1.67)
Pancreas 44 2.90 (2.10, 3.89) 58 1.31 (1.00, 1.70) 55 1.50 (1.13, 1.95) 66 1.40 (1.08, 1.78) 223 1.56 (1.36, 1.78) 179 1.40 (1.20, 1.62)
Lung 285 6.98 (6.19, 7.84) 294 2.41 (2.14, 2.70) 186 1.76 (1.52, 2.04) 170 1.20 (1.03, 1.40) 935 2.28 (2.14, 2.43) 650 1.76 (1.63, 1.90)
Breast 71 1.09 (0.85, 1.38) 221 1.05 (0.91, 1.20) 172 0.89 (0.76, 1.04) 297 1.07 (0.95, 1.20) 761 1.02 (0.95, 1.09) 690 1.01 (0.94, 1.09)
Cervix 11 1.79 (0.89, 3.21) 30 1.56 (1.05, 2.23) 20 1.18 (0.72, 1.83) 32 1.28 (0.87, 1.81) 93 1.38 (1.11, 1.69) 82 1.34 (1.07, 1.66)
Endometrium 18 1.18 (0.70, 1.87) 36 0.74 (0.52, 1.02) 30 0.68 (0.46, 0.98) 45 0.76 (0.55, 1.01) 129 0.77 (0.64, 0.92) 111 0.73 (0.60, 0.88)
Ovary 19 1.60 (0.96, 2.50) 38 1.02 (0.72, 1.40) 29 0.89 (0.60, 1.28) 38 0.87 (0.61, 1.19) 124 0.99 (0.82, 1.18) 105 0.92 (0.76, 1.12)
Prostate 178 2.12 (1.82, 2.45) 346 1.38 (1.24, 1.53) 265 1.19 (1.05, 1.35) 397 1.26 (1.14, 1.39) 1186 1.36 (1.29, 1.44) 1008 1.28 (1.20, 1.36)
Kidney 38 2.40 (1.70, 3.30) 71 1.55 (1.21, 1.95) 60 1.61 (1.23, 2.07) 38 0.79 (0.56, 1.08) 207 1.41 (1.22, 1.61) 169 1.29 (1.10, 1.50)
Urinary bladder 59 2.21 (1.68, 2.85) 117 1.47 (1.21, 1.76) 87 1.26 (1.01, 1.56) 113 1.21 (1.00, 1.45) 376 1.40 (1.26, 1.55) 317 1.31 (1.17, 1.46)
Melanoma 15 1.02 (0.57, 1.69) 30 0.63 (0.43, 0.90) 42 0.93 (0.67, 1.26) 65 0.89 (0.68, 1.13) 152 0.84 (0.71, 0.99) 137 0.83 (0.69, 0.98)
Skin, squamous cell 36 1.56 (1.09, 2.16) 92 1.28 (1.03, 1.57) 83 1.30 (1.04, 1.61) 116 1.32 (1.09, 1.59) 327 1.33 (1.19, 1.48) 291 1.30 (1.16, 1.46)
Nervous system 48 3.01 (2.22, 3.99) 57 1.13 (0.86, 1.47) 51 1.15 (0.85, 1.51) 66 1.08 (0.84, 1.38) 222 1.29 (1.13, 1.48) 174 1.12 (0.96, 1.30)
Endocrine glands 28 3.11 (2.07, 4.51) 33 1.18 (0.81, 1.67) 29 1.19 (0.79, 1.70) 37 1.07 (0.75, 1.47) 127 1.32 (1.10, 1.57 99 1.14 (0.92, 1.39)
Non-Hodgkin’s lymphoma 42 1.87 (1.35, 2.53) 54 0.78 (0.58, 1.02) 47 0.77 (0.56, 1.02) 87 1.03 (0.82, 1.27) 230 0.97 (0.85, 1.10) 188 0.87 (0.75, 1.01)
Myeloma 13 1.65 (0.87, 2.82) 24 1.02 (0.65, 1.52) 21 1.05 (0.65, 1.60) 31 1.16 (0.79, 1.65) 89 1.14 (0.91, 1.40) 76 1.08 (0.85, 1.35)
Leukaemia 40 3.25 (2.32, 4.42) 56 1.51 (1.14, 1.96) 47 1.56 (1.15, 2.08) 45 1.24 (0.90, 1.65) 188 1.62 (1.40, 1.87) 148 1.43 (1.21, 1.68)
All 1264 2.40 (2.27, 2.54) 2205 1.38 (1.32, 1.44) 1700 1.21 (1.15, 1.27) 2252 1.16 (1.11, 1.21) 7421 1.36 (1.33, 1.39) 6157 1.24 (1.21, 1.28)
CI¼confidence interval; SIR¼standardised incidence ratio. Bold values represent 95% CI that does not include 1.00. Underlined values represent 99% CI that does not include
1.00.
Table 2 SIR for subsequent cancer in patients hospitalised for asthma by number of hospitalisations
Number of hospitalisations
12 – 5 X6
Cancer site O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 65 1.15 (0.89, 1.47) 43 1.31 (0.95, 1.76) 7 0.62 (0.24, 1.28)
Oesophagus 39 1.72 (1.22, 2.36) 30 2.21 (1.49, 3.16) 7 1.45 (0.57, 3.00)
Stomach* 98 1.11 (0.90, 1.35) 81 1.54 (1.22, 1.92) 31 1.70 (1.15, 2.41)
Colon** 302 1.43 (1.27, 1.60) 212 1.66 (1.44, 1.90) 91 1.99 (1.60, 2.44)
Rectum 149 1.28 (1.08, 1.51) 78 1.12 (0.88, 1.40) 35 1.42 (0.99, 1.98)
Liver 110 1.47 (1.21, 1.77) 61 1.35 (1.03, 1.73) 26 1.62 (1.06, 2.38)
Pancreas 97 1.37 (1.11, 1.67) 59 1.39 (1.06, 1.80) 23 1.55 (0.98, 2.33)
Lung** 402 1.96 (1.78, 2.16) 190 1.56 (1.35, 1.80) 58 1.36 (1.04, 1.76)
Breast 399 1.04 (0.94, 1.14) 217 0.98 (0.85, 1.12) 74 0.99 (0.78, 1.24)
Cervix 46 1.30 (0.95, 1.73) 28 1.43 (0.95, 2.07) 8 1.29 (0.55, 2.55)
Endometrium 67 0.79 (0.62, 1.01) 36 0.71 (0.50, 0.99) 8 0.46 (0.19, 0.90)
Ovary 60 0.93 (0.71, 1.20) 34 0.92 (0.63, 1.28) 11 0.90 (0.44, 1.61)
Prostate 525 1.21 (1.11, 1.32) 359 1.37 (1.24, 1.52) 124 1.33 (1.10, 1.58)
Kidney 94 1.27 (1.03, 1.56) 52 1.21 (0.90, 1.59) 23 1.59 (1.00, 2.38)
Urinary bladder 189 1.42 (1.22, 1.63) 97 1.21 (0.98, 1.48) 31 1.09 (0.74, 1.55)
Melanoma 72 0.76 (0.59, 0.95) 48 0.90 (0.66, 1.19) 17 0.97 (0.57, 1.56)
Skin, squamous cell 151 1.25 (1.06, 1.47) 94 1.26 (1.02, 1.54) 46 1.64 (1.20, 2.19)
Nervous system 93 1.01 (0.81, 1.23) 58 1.19 (0.91, 1.54) 23 1.58 (1.00, 2.38)
Endocrine glands 70 1.42 (1.11, 1.79) 23 0.81 (0.51, 1.22) 6 0.64 (0.23, 1.40)
Non-Hodgkin’s lymphoma 90 0.75 (0.60, 0.92) 71 0.01 (0.79, 1.27) 27 1.11 (0.73, 1.62)
Myeloma 42 1.08 (0.78, 1.47) 24 1.03 (0.66, 1.54) 10 1.21 (0.58, 2.24)
Leukaemia 89 1.46 (1.17, 1.80) 47 1.45 (1.07, 1.93) 12 1.18 (0.61, 2.07)
All 3407 1.23 (1.19, 1.27) 2028 1.25 (1.20, 1.30) 722 1.29 (1.20, 1.38)
CI¼confidence interval; SIR¼standardised incidence ratio. Bold values values represent 99% CI that does not include 1.00. *P-value for trend is o0.05. **P-value for trend is
o0.01.
Cancer risk in asthma patients
JJ iet al
830












ywas divided into four periods: o1, 1–4, 5–9 and X10 years.
Standardised incidence ratios (SIRs) were calculated as the ratio of
observed to expected number of cases. The expected numbers were
calculated by the incidence rates for all individuals without a
history of asthma, and the incidence rates in the reference group
were similar to the general population in our database. The rates
were standardized by 5-year age, gender, period (5-year group),
socioeconomic status, and residential area (Esteve et al, 1994).
For cancers of the female reproductive system, age at first
childbirth and parity were also standardised. The 95% confidence
interval of the SIR was calculated assuming a Poisson distribution,
and they were rounded to the nearest two decimals (Esteve et al,
1994). Temporal trend was tested based on the w
2 distribution of
the test statistic w
2 with 1 degree of freedom. All analyses were
performed using the SAS statistical package (version 9.1; SAS
Institute, Cary, NC, USA). The ethics committee at Karolinska
Institute, Stockholm, Sweden, approved this study.
RESULTS
A total of 140425 patients were hospitalised in Sweden for asthma
during 1965–2004; among them 83098 (59.2%) patients were
hospitalised only once, 22338 (15.9%) twice, 10253 (7.3%) thrice,
5836 (4.2%) for four times, 3717 (2.7%) for five times, and 15183
(8.7%) for more than five times. A total of 7421 patients developed
subsequent cancer after being hospitalised for asthma, giving an
overall SIR of 1.36 and a SIR of 1.24 for cancer diagnosed later than
1 year of the last hospital admission (all 1þ), as shown in Table 1.
Only those cancer sites with at least 60 cases during the whole
follow-up period were listed. The risk for some cancer sites, such
as lung cancer and leukaemia, was high during the first year,
probably because of a concomitant diagnosis of asthma and
cancer. Thus, we show the data for the whole follow-up period and
1þ, respectively; the results agreed for significant increases and
decreases for almost all the examined cancers. The highest overall
increase of 2.28 was noted for lung cancer, and the increases
were noted in the whole follow-up periods. Even all the other
cancers, with an exception for breast and ovarian cancers and
non-Hodgkin’s lymphoma and myeloma, showed a significantly
increased SIR. A significantly decreased SIR was noted for
endometrial cancer (0.77) and skin melanoma (0.84).
Multiple hospital admissions may reflect the disease severity,
and we examined cancer risk by the number of hospital admissions
by starting the follow-up after the last admission (Table 2). The
overall SIR was 1.23 for asthma patients who have been
hospitalised once, and it was slightly increased to 1.25 for those
with 2–5 hospital admissions and to 1.29 for those with more than
five hospital admissions. The SIR was higher for almost all cancers
when asthma patients had multiple hospital admissions, with an
exception for lung, bladder and endocrine gland tumours, and
leukaemia. We tested for the significance of the trend in the
number of hospital admissions (see asterisk after ‘cancer site’).
Stomach and colon cancers and non-Hodgkin’s lymphoma showed
an increasing trend with the number of admissions, whereas a
reverse trend was noted for lung cancer. In those hospitalised
more than five times, the SIR of kidney cancer exceeded that of
lung cancer.
To study the periodic effects in respect to the changing
therapeutic regimens and diagnosis criteria, we analysed cancer
risk among asthma patients who were hospitalised in the 1970s,
1980s, and 1990s (Table 3). As maximally 14 years could be
followed up for those who had been hospitalised in the 1990s,
analyses were limited to cancers diagnosed 1–14 years after the
last hospital admission. The overall SIR was marginally higher
for the patients hospitalised in the 1970s compared with
those hospitalised later. The highest risk (2.79) was noted for
oesophageal cancer when patients were hospitalised in the 1990s.
We tested for the significance of the temporal trends. The risk for
stomach cancer and melanoma showed an increasing temporal
trend, whereas a reverse trend was noted for non-Hodgkin’s
lymphoma.
Table 3 SIR for subsequent cancer in patients with hospitalised asthma during diagnosis period
1970s 1980s 1990s
Cancer site O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 12 0.92 (0.47, 1.62) 44 1.17 (0.85, 1.57) 35 1.27 (0.88, 1.77)
Oesophagus 12 2.73 (1.40, 4.78) 18 1.18 (0.70, 1.87) 34 2.79 (1.93, 3.91)
Stomach** 22 0.92 (0.58, 1.39) 81 1.36 (1.08, 1.69) 71 1.67 (1.30, 2.10)
Colon 63 1.69 (1.30, 2.17) 216 1.54 (1.34, 1.75) 201 1.67 (1.45, 1.92)
Rectum 32 1.51 (1.03, 2.14) 81 1.04 (0.83, 1.30) 83 1.29 (1.03, 1.60)
Liver 33 1.98 (1.36, 2.78) 87 1.70 (1.36, 2.10) 54 1.35 (1.01, 1.76)
Pancreas 18 1.11 (0.66, 1.76) 79 1.66 (1.32, 2.08) 49 1.32 (0.97, 1.74)
Lung 96 2.31 (1.87, 2.83) 215 1.58 (1.38, 1.81) 238 2.21 (1.94, 2.51)
Breast 63 1.09 (0.84, 1.40) 239 1.01 (0.88, 1.14) 205 0.93 (0.81, 1.07)
Cervix 14 1.68 (0.92, 2.83) 29 1.39 (0.93, 2.00) 20 1.22 (0.74, 1.89)
Endometrium 8 0.64 (0.27, 1.27) 41 0.77 (0.55, 1.05) 41 0.79 (0.56, 1.07)
Ovary 16 1.23 (0.70, 2.01) 38 0.94 (0.67, 1.29) 28 0.81 (0.54, 1.17)
Prostate 97 1.38 (1.12, 1.68) 362 1.22 (1.10, 1.35) 303 1.28 (1.14, 1.43)
Kidney 17 1.00 (0.58, 1.61) 70 1.46 (1.14, 1.84) 61 1.61 (1.23, 2.07)
Urinary bladder 41 1.63 (1.17, 2.21) 115 1.27 (1.04, 1.52) 92 1.29 (1.04, 1.58)
Melanoma* 6 0.39 (0.14, 0.85) 45 0.77 (0.56, 1.03) 45 0.95 (0.69, 1.27)
Skin, squamous cell 18 1.13 (0.67, 1.78) 104 1.25 (1.02, 1.51) 96 1.32 (1.07, 1.61)
Nervous system 23 1.30 (0.82, 1.95) 75 1.41 (1.11, 1.76) 40 0.83 (0.59, 1.13)
Endocrine glands 14 1.49 (0.81, 2.50) 41 1.32 (0.95, 1.80) 28 1.09 (0.72, 1.58)
Non-Hodgkin’s lymphoma** 21 1.39 (0.86, 2.13) 76 1.26 (0.99, 1.58) 45 0.85 (0.62, 1.14)
Myeloma 4 0.53 (0.14, 1.38) 31 1.19 (0.81, 1.69) 22 1.03 (0.65, 1.57)
Leukaemia 16 1.00 (0.57, 1.64) 50 0.94 (0.70, 1.24) 56 1.11 (0.84, 1.44)
All 675 1.35 (1.25, 1.45) 2213 1.23 (1.18, 1.28) 1932 1.29 (1.23, 1.34)
CI¼confidence interval; SIR¼standardised incidence ratio. Bold values represent 95% CI that does not include 1.00. Underline values represent 99% CI that does not include
1.00. *P-value for trend is o0.05. **P-value for trend is o0.01.
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In this population-based study, 140425 asthma patients were
identified from the Swedish Hospital Discharge Register and were
followed up to 40 years, an observation time longer than that in
any published study on this theme. The additional strengths of our
study include its population-based prospective design and
completeness of follow-up of the patients. All the data were from
nation-wide databases guaranteeing reliable information. One
limitation of this study is that because multiple comparisons were
performed, some of the findings may be due to chance. The lack of
information regarding medication and treatment and regarding
the possible confounding factors, such as smoking, is another
limitation. Moreover, the data from this study are not directly
applicable to all patients with asthma because outpatients were not
included in this study and hospitalised patients probably represent
a severe and chronic clientele.
Overall, a 36% excess incidence of cancer was noted among
asthma patients who had been treated in hospitals. Most earlier
studies reported a reverse association or no association between
asthma and the overall cancer risk (Kallen et al, 1993; Turner et al,
2005, 2006); a Swedish study from the earlier days of the
Hospital Discharge Register reported a decreased mortality of 66%
(Kallen et al, 1993). According to a recent review on cancer risk in
asthma (Turner et al, 2006), only one Finnish cohort study has
shown a positive association (Vesterinen et al, 1993), but
significant only for men. The number of cancer cases in our
study was almost the sum of cases in three earlier cohort studies
(Kallen et al, 1993; Vesterinen et al, 1993; Turner et al, 2005). For
the cancers overall, the highest risks were noted during the first
year after last hospital admission for asthma, which could be due
to lead time bias because of concomitant diagnosis. However, these
earlier cancers were so few that the SIRs calculated for the whole
follow-up period and for the whole period minus the first year
were basically unchanged.
For specific cancers, some of the observed associations have
been reported earlier. The increased risk for lung cancer was noted
in many earlier studies (Vesterinen et al, 1993; Huovinen et al,
1997; Mayne et al, 1999; Boffett et al, 2002). Smoking is a common
risk factor for lung cancer and asthma (Silverman et al, 2003;
Eisner, 2008). The excess of bladder and kidney cancers in our
study may also reflect confounding by smoking; however, the data
on the number of hospital admissions and on temporal trends for
kidney and lung cancers suggest that non-smoking-related factors
contribute to kidney cancer, particularly towards the end of the
study period. An increase in oesophageal and stomach cancers was
reported earlier and partly attributed to gastro-oesophageal reflux
caused by b-adrenergic medication (Ye et al, 2001). A significant
increase of rectal cancer has been reported among Finnish women
(Vesterinen et al, 1993), whereas an excess of prostate cancer
has been reported in cohort studies from Japan and Australia
(Ohrui et al, 2002; Talbot-Smith et al, 2003).
The increased risks in cancers of the colon, liver, and pancreas
have not been reported earlier and most earlier studies have shown
a reduced risk or risk close to unity (Vesterinen et al, 1993;
Talbot-Smith et al, 2003; Turner et al, 2005). The excess of colon
cancer increased with the number of hospital admissions and the
SIR was 1.99 for those hospitalised more than 5 times, highest for
any cancer, suggesting a true aetiological link. IL-6 trans-signalling
is critically involved in the maintenance of both asthma and colon
cancer (Scheller et al, 2006). Asthma medications may also play a
role in this association (Friedman et al, 1998). Although a recent
review reported no association with pancreatic cancer (Turner
et al, 2006), a 56% excess was noted in our study and the risk was
significant even after 1 year of hospital admission. An increased
occurrence of squamous cell skin cancer has not been reported
earlier. This cancer is one of the hallmarks of dysregulated
immunity; another hallmark, non-Hodgkin’s lymphoma, showed
no increase and a decrease in those hospitalised only once. The
decrease in endometrial cancer raised the possibility that
dysregulated immune function among asthma patients may affect
oestrogen production (Ahmed et al, 1999; Hemminki et al, 2008).
The only other tumour with a decreased risk was melanoma, but
only in asthmatics diagnosed in the 1970s. The increase in cervical
cancer may signal vulnerability to infection by human papilloma-
viruses; immune impairment is a risk factor for cervical cancer. In
contrast to the inverse association between asthma and leukaemia
in the earlier studies, an increased risk was noted in our study. The
positive associations with cancers of the upper aerodigestive tract,
nervous system, and endocrine glands were confined for the first
year after hospital admission, suggesting that they were due to the
lead-time bias.
We examined the study group by the number of hospital
admissions, using this as a surrogate for disease severity and
chronicity. The overall cancer risk was not affected, but there were
large differences by cancer types. The excess in stomach, colon,
liver and skin cancers were most pronounced with multiple
hospital admissions, and so was the protection in endometrial
cancer. For oesophageal cancer, the highest risk of 2.21 was noted
for those hospitalised 2–5 times. The two-fold risk of colon cancer
may indicate medical surveillance.
The diagnostic criteria and treatment for asthma patients
have changed during the follow-up period. We examined the
temporal trends of cancer development among asthma patients.
The overall risk was marginally higher for patients hospitalised in
the 1970s compared with the later periods, and for the most
specific cancers the risk did not change or decreased slightly
during the study period. In view of the large increase in
medications, the relatively constant risks observed throughout
the study period suggest that the medical condition ‘asthma’ rather
than its medication may be associated with cancer risk. However,
the increasing temporal trend for stomach cancer calls for clinical
attention.
In summary, a 36% excess incidence of cancer was noted among
asthma patients. The robust relative risks and their consistency
with multiple hospital admissions suggest real associations with
several cancer sites and protection for endometrial cancer, more
likely with the disorder than with its medication.
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